Apellis Pharmaceuticals (APLS) Receives Analyst Upgrade: A Closer Look
Apellis Pharmaceuticals, a prominent name in the biopharmaceutical industry, has been making waves with its new eye disease treatment. On October 6, 2023, JP Morgan issued a noteworthy upgrade for the Apellis (APLS), changing its previous “Neutral” rating to “Overweight.” This upgrade suggests a bullish sentiment towards the stock’s future performance. Alongside this rating change, …
Apellis Pharmaceuticals (APLS) Receives Analyst Upgrade: A Closer Look Read More »